ROS1 and non-small cell lung carcinoma: The most common activating alterations of ROS1 in NSCLC are gene fusion with the solute carrier family 34 member 2 (SLC34A2) and CD74, as well as protein overexpression, gene amplification and mutations [28,29,30,31].